Swiss pharmaceutical giant Roche announced a $2.3 billion partnership with Nurix Therapeutics to develop blood cancer treatments, marking one of the largest biotech deals in recent months.

Under the agreement, Roche will pay Nurix $700 million upfront, with the companies splitting development costs on a 60-40 basis, with Roche bearing the larger share. The deal focuses on advancing Nurix's blood cancer drug portfolio through clinical development and potential commercialization.

Separately, consumer healthcare company Haleon revealed plans to invest $233.5 million in a new manufacturing facility in Madhya Pradesh, India. The plant will produce oral health products and represents the largest manufacturing investment the company has undertaken to date.

The India facility is part of Haleon's broader strategy to expand operations in emerging markets, where the company sees significant growth opportunities for its consumer health products.

Both announcements reflect continued consolidation and expansion in the pharmaceutical sector, with companies seeking to strengthen their drug pipelines through partnerships and expand manufacturing capabilities in key global markets.